Oxytrol For Women
Nocturia, Urinary Bladder, Overactive, Neurological Disorders + 8 more
Treatment
20 Active Studies for Oxytrol For Women
Treatment for
Nocturia
What is Oxytrol For Women
Oxybutynin
The Generic name of this drug
Treatment Summary
Oxybutynin, also known as Ditropan XL, is a medication used to treat overactive bladder (OAB). OAB is a common condition that causes symptoms like frequent urination and urgency. Oxybutynin was first approved by the FDA in 1975 and is considered a safe and effective treatment for OAB. It can help improve the quality of life for people affected by OAB by relieving their symptoms. It is often the first drug prescribed for OAB.
Ditropan
is the brand name
Oxytrol For Women Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ditropan
Oxybutynin
1975
256
Effectiveness
How Oxytrol For Women Affects Patients
Oxybutynin helps to relieve symptoms of an overactive bladder, such as frequent and urgent urination, by blocking a certain type of nerve receptor. Taking this drug may cause symptoms of angioedema, so it should be stopped immediately if this occurs. It can also cause anticholinergic effects such as hallucinations, confusion, agitation, and drowsiness, and using heavy machinery should be avoided until the response to oxybutynin is known. The dose may need to be adjusted in some cases.
How Oxytrol For Women works in the body
Oxybutynin works by blocking the effects of a chemical called acetylcholine on bladder muscles, which makes it easier to control urine flow and decreases urgency and frequency of urination. It does this by preventing the chemical from binding to receptors in the bladder muscles. Oxybutynin's active metabolite is N-desethyloxybutynin, which works to relax the bladder and increase its capacity.
When to interrupt dosage
The suggested measure of Oxytrol For Women is contingent upon the diagnosed condition, including Neurological Disorders, Foley Catheterization and Nocturia. The sum of dosage varies according to the method of delivery (e.g. Tablet, extended release or Patch) recorded in the table underneath.
Condition
Dosage
Administration
Spinal Dysraphism
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Urinary Bladder, Overactive
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Neurological Disorders
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
increased frequency of urination
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Foley Catheterization
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Longterm Indwelling Ureteral Stent
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Nocturia
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Bladder Spasms
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Urinary Urgency
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Urinary Incontinence, Urge
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Overactive Bladder Syndrome
, 5.0 mg/mL, 10.0 mg, 15.0 mg, 5.0 mg, 0.39 mg/hour, 0.28 mg/mg, 0.1 mg/mg, 2.5 mg, 0.0907 mg/mg, 10.0 %, 1.0 mg/mL
, Syrup, Oral, Syrup - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Gel, Gel - Transdermal, Transdermal, Topical, Gel - Topical, Solution, Solution - Oral, Patch - Transdermal, Spray, metered, Spray, metered - Topical, Patch
Warnings
Oxytrol For Women Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Oxybutynin may interact with Pulse Frequency
Urinary Retention
Do Not Combine
uncontrolled narrow-angle glaucoma
Do Not Combine
Gastric Retention
Do Not Combine
There are 20 known major drug interactions with Oxytrol For Women.
Common Oxytrol For Women Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Oxybutynin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Oxybutynin.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Aclidinium.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Oxybutynin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Oxybutynin.
Oxytrol For Women Toxicity & Overdose Risk
The lowest fatal dose of oxybutynin in rats is 460mg/kg. If someone overdoses on oxybutynin, they may experience confusion, fever, rapid heartbeat, urinary retention, difficulty breathing, paralysis and coma. Immediate supportive care should be provided, as well as activated charcoal and a laxative. There have been two cases of people overdosing on 100mg of oxybutynin, both of which involved alcohol consumption. Both individuals received treatment and fully recovered.
Oxytrol For Women Novel Uses: Which Conditions Have a Clinical Trial Featuring Oxytrol For Women?
79 active clinical trials are currently examining the potential of Oxytrol For Women to provide relief from Overactive Bladder Syndrome, Foley Catheterization and Neurological Disorders.
Condition
Clinical Trials
Trial Phases
Nocturia
3 Actively Recruiting
Phase 4, Not Applicable
Bladder Spasms
1 Actively Recruiting
Phase 2
Spinal Dysraphism
0 Actively Recruiting
Urinary Incontinence, Urge
7 Actively Recruiting
Not Applicable, Phase 4
Foley Catheterization
0 Actively Recruiting
Urinary Urgency
2 Actively Recruiting
Not Applicable
Urinary Bladder, Overactive
0 Actively Recruiting
Overactive Bladder Syndrome
32 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 1, Phase 2
Longterm Indwelling Ureteral Stent
0 Actively Recruiting
Neurological Disorders
7 Actively Recruiting
Not Applicable, Phase 2
increased frequency of urination
3 Actively Recruiting
Not Applicable
Oxytrol For Women Reviews: What are patients saying about Oxytrol For Women?
5
Patient Review
2/9/2014
Oxytrol For Women for A Condition of Bladder Dysfunction from Nerve Disorder
5
Patient Review
3/12/2014
Oxytrol For Women for Overactive Bladder
4.3
Patient Review
5/18/2014
Oxytrol For Women for Urine Leakage When there is a Strong Desire to Void
4
Patient Review
5/28/2014
Oxytrol For Women for Needing to Urinate Immediately
3.7
Patient Review
11/20/2014
Oxytrol For Women for Overactive Bladder
3.7
Patient Review
10/31/2013
Oxytrol For Women for Overactive Bladder
1.3
Patient Review
11/17/2013
Oxytrol For Women for Overactive Bladder
Patient Q&A Section about oxytrol for women
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Can you buy Oxytrol over-the-counter?
"The Oxytrol patches for men and women are available in different forms. The men's patch is available only with a doctor's prescription, but the women's patch is available without a prescription or over-the counter (OTC). This product is available in the following dosage forms: Patch, Extended Release."
Answered by AI
What are the side effects of Oxytrol patch?
"You may experience skin redness or irritation, dry mouth, drowsiness, dizziness, blurred vision, headache, weakness, nausea, or constipation when using this medication. If you experience any of these symptoms, tell your doctor or pharmacist."
Answered by AI
How long does it take for Oxytrol to start working?
"It takes approximately one week for the medication to reach steady levels in your system after you start using Oxytrol patches. The patches deliver the medication slowly through your skin and into your bloodstream over the course of 3-4 days."
Answered by AI
Why was Oxytrol patch discontinued?
"Because sales were not meeting expectations, Bayer AG stopped distributing the over-the-counter version of OXY-TDS in early 2015, after they acquired Merck & Co."
Answered by AI